Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030

Outsourcing
has become a popular trend among biopharmaceutical developers, allowing them to
leverage the expertise / larger production capacities of CMOs / CDMOs and
achieve significant cost and time related advantages

Roots
Analysis is pleased to announce the publication of its recent study, titled, “Biopharma
Contract Manufacturing Market,
2021-2030.” 

The
report features an extensive study on the contract service providers within the
biopharmaceutical industry. The study features in-depth analysis, highlighting
the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst
other elements, the report includes:

·       
A detailed review of the overall landscape of
the biopharmaceutical contract manufacturing market, featuring a comprehensive
list of active CMOs and detailed analysis of the manufacturing service
providers based on a number of parameters.

·       
Elaborate profiles of key players that have a
diverse range of capabilities for the development, manufacturing, and packaging
of biologics.

·       
A detailed discussion on the key enablers in
this domain, including certain niche product classes, which are likely to have
a significant impact on the growth of the contract services market.

·       
A case study on the growing global
biosimilars market, highlighting the opportunities for biopharmaceutical CMOs
and CDMOs.

·       
A case study comparing the key
characteristics of large molecule and small molecule drugs, along with details
on the various steps involved in their respective manufacturing processes.

·       
A discussion on challenges related to
in-house manufacturing, featuring a brief overview of the various parameters
that a drug / therapy developer may need to take into consideration while
deciding whether to manufacture its products in-house or outsource.

·       
An analysis of the recent collaborations
(signed since 2013) focused on the contract manufacturing of biologics.

·       
A detailed analysis of the various mergers
and acquisitions that have taken place in this domain, highlighting the trend
in the number of companies acquired between 2013-2018, along with the
geographical distribution of this activity.

·       
An in-depth analysis of more than 490 grants
that have been awarded to research institutes engaged in next generation immune
checkpoint therapy-related projects.

·       
An analysis on the recent trends within
biopharmaceutical contract manufacturing industry, highlighting various
facility and capability expansions.

·       
A detailed capacity analysis, taking into
consideration the individual development and manufacturing capacities of
various stakeholders.

·       
A detailed capacity analysis, taking into
consideration the individual development and manufacturing capacities of
various stakeholders.

·       
A discussion on affiliated trends, key
drivers, and challenges, under a comprehensive SWOT framework.

·       
A survey analysis featuring inputs solicited
from various experts who are directly / indirectly involved in providing CMO
services to medical device developers.